A cultured autologous dermo-epidermal skin substitute for full-thickness skin defects: a phase I, open, prospective clinical Trial in children by Meuli, Martin et al.








A cultured autologous dermo-epidermal skin substitute for full-thickness
skin defects: a phase I, open, prospective clinical Trial in children
Meuli, Martin ; Hartmann-Fritsch, Fabienne ; Hüging, Martina ; Marino, Daniela ; Saglini, Monia ;
Hynes, Sally ; Neuhaus, Kathrin ; Manuel, Edith ; Middelkoop, Esther ; Reichmann, Ernst ; Schiestl,
Clemens
Abstract: BACKGROUND: The management of deep partial-thickness and full-thickness skin defects
remains a significant challenge. Particularly with massive defects, the current standard treatment, split-
thickness skin grafting, is fraught with donor-site limitations and unsatisfactory long-term outcomes. A
novel, autologous, bioengineered skin substitute was developed to address this problem. METHODS: To
determine whether this skin substitute could safely provide permanent defect coverage, a phase I clinical
trial was performed at the University Children’s Hospital Zurich. Ten pediatric patients with acute or
elective deep partial- or full-thickness skin defects were included. Skin grafts of 49 cm were bioengineered
using autologous keratinocytes and fibroblasts isolated from a patient’s small skin biopsy specimen (4
cm), incorporated in a collagen hydrogel. RESULTS: Graft take, epithelialization, infection, adverse
events, skin quality, and histology were analyzed. Median graft take at 21 days postoperatively was 78
percent (range, 0 to 100 percent). Healed skin substitutes were stable and skin quality was nearly normal.
There were four cases of hematoma leading to partial graft loss. Histology at 3 months revealed a well-
stratified epidermis and a dermal compartment comparable to native skin. Mean follow-up duration was
15 months. CONCLUSIONS: In the first clinical application of this novel skin substitute, safe coverage
of skin defects was achieved. Safety and efficacy phase II trials comparing the novel skin substitute to
split-thickness skin grafts are ongoing. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic,
IV.
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T
he management of deep partial-thickness 
and full-thickness skin defects remains chal-
lenging, with a broad spectrum of clinical 
problems ranging from rare, massive, deep burns 
in healthy patients to common, small ulcers in 
elderly people with multiple morbidities. The 
common denominator is the need for perma-
nent skin coverage that provides the patient with 
a long-term result that is stable and functionally 
and aesthetically optimal.
Small defects can be covered with full-thickness 
skin grafts harvested from the patient with usually 
excellent results. However, there is a marked donor-
site shortage. Thus, for larger defects, most notably 
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Background: The management of deep partial-thickness and full-thickness skin 
defects remains a significant challenge. Particularly with massive defects, the 
current standard treatment, split-thickness skin grafting, is fraught with donor-
site limitations and unsatisfactory long-term outcomes. A novel, autologous, 
bioengineered skin substitute was developed to address this problem.
Methods: To determine whether this skin substitute could safely provide per-
manent defect coverage, a phase I clinical trial was performed at the University 
Children’s Hospital Zurich. Ten pediatric patients with acute or elective deep 
partial- or full-thickness skin defects were included. Skin grafts of 49 cm2 were 
bioengineered using autologous keratinocytes and fibroblasts isolated from 
a patient’s small skin biopsy specimen (4 cm2), incorporated in a collagen 
hydrogel.
Results: Graft take, epithelialization, infection, adverse events, skin quality, and 
histology were analyzed. Median graft take at 21 days postoperatively was 78 
percent (range, 0 to 100 percent). Healed skin substitutes were stable and 
skin quality was nearly normal. There were four cases of hematoma leading 
to partial graft loss. Histology at 3 months revealed a well-stratified epidermis 
and a dermal compartment comparable to native skin. Mean follow-up dura-
tion was 15 months.
Conclusions: In the first clinical application of this novel skin substitute, safe 
coverage of skin defects was achieved. Safety and efficacy phase II trials compar-
ing the novel skin substitute to split-thickness skin grafts are ongoing. (Plast. 
Reconstr. Surg. 144: 188, 2019.)
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burns, split-thickness skin grafts remain the standard 
treatment, often applied with expansion techniques, 
such as meshing or Meek micrografting.1,2 Here, the 
results are less favorable, with a risk of functionally 
debilitating and disfiguring scars, particularly in 
children.3 Furthermore, split-thickness skin grafts 
increase the patient’s wound healing burden, and, 
in massive burns, donor-site limitations cause delays 
in definitive coverage that may lead to sepsis, mul-
tiple organ dysfunction, and death.4
Clearly, culturing epidermis from the patient’s 
own cells, as envisioned by Rheinwald and Green 
40 years ago,5,6 was revolutionary and has fostered 
intense research during recent decades. Unfortu-
nately, cultured epithelial autografts remain fraught 
with considerable problems when used for the cov-
erage of deep skin defects, including graft fragility, 
poor take, instability of healed grafts, and unsatisfac-
tory long-term functional and aesthetic results.2,7–9 
The clinical introduction of nowadays widely used 
dermal regeneration templates [e.g., Integra Der-
mal Regeneration Template (Integra LifeSciences 
Corp., Plainsboro, N.J.), Matriderm (MedSkin Solu-
tions Dr. Suwelack AG, Billerbeck, Germany)] has 
pushed the frontiers further, carrying the potential 
for improved functional and aesthetic results, yet 
such templates still require coverage with an overly-
ing autologous split-thickness skin graft.10
In the early 1990s, the first cultured autologous 
dermo-epidermal skin substitute, developed by 
Hansbrough et al., was successfully applied clini-
cally for “compassionate use” in severe burns,11 and 
has more recently been investigated in a clinical 
trial setting.12 However, more than 25 years since 
its introduction, this skin analogue is still not com-
mercially available. Another bioengineered dermo-
epidermal skin substitute, developed at LOEX 
(Quebec City, Quebec, Canada), was introduced in 
preclinical studies13 and as biological dressing.14
Here, we report on a novel, bioengineered, 
hydrogel-based, autologous, dermo-epidermal 
skin substitute used in a first-in-human clinical 
trial in children. These grafts are based on plas-
tically compressed collagen type I hydrogels with 
incorporated keratinocytes and fibroblasts that 
proliferate and differentiate. It features an epi-
dermis that correctly stratifies on grafting, seems 
to develop a functional basement membrane and 
dermo-epidermal junction, and demonstrates a 
nearly normal, functional dermis. The results of 
the preclinical studies on immunoincompetent 
rats and a porcine large-animal model strongly 
support the envisioned application in humans.15–19
Collagen hydrogels have been used as experi-
mental tissue scaffolds20 and in the commercially 
available allogeneic skin substitute Apligraf 
(Organogenesis, Canton, Mass.). However, there 
are no reports of a hydrogel-based skin substi-
tute composed of purely autologous cells that 
safely and permanently replaces skin on human 
patients.
PATIENTS AND METHODS
Study Design and Participants
Ten patients (defined using power analysis) 
presenting to the Division of Plastic and Recon-
structive Surgery at the University Children’s Hos-
pital Zurich for management of deep partial- or 
full-thickness skin defects, or reconstruction of 
skin lesions, were recruited for this phase I clinical 
trial. No rules to stop data collection in advance 
were defined. Inclusion and exclusion criteria 
and the study flow chart are outlined in Figure 1. 
Outliers were included in the analysis.
This clinical trial conforms to the Declaration 
of Helsinki and the guidelines for Good Clini-
cal Practice and follows the European Medicines 
Agency guidelines for Advanced Therapy Medici-
nal Products. The trial was approved by the local 
ethical committee Zurich (KEK-ZH-Nr.2012-0573) 
and by Swissmedic (2013TpP1004). All patients/
legal representatives received detailed informa-
tion about the study. Biopsies, operations, and 
all associated procedures were performed after 
informed consent was obtained.
The main objective was safety evaluation of 
the skin substitute. The experimental design was 
a phase I, two-armed, open, prospective study 
to evaluate the safety of autologous tissue-engi-
neered dermo-epidermal skin substitutes for the 
treatment of large deep partial- and full-thickness 
skin defects in children and adolescents. The 
experimental arm was transplantation of 49 cm2 
of the novel graft. The primary endpoints were 
graft take at 21 days postoperatively and infection 
rate, and the secondary endpoint was assessment 
and reporting of adverse events.
Biopsy
A split-thickness skin biopsy specimen measur-
ing 4 cm2 was harvested from the retroauricular 
scalp using an electric dermatome, with either 
local or general anesthesia, depending on the 
child’s age and the need for concomitant surgery.
Skin Manufacturing
Manufacturing, in accordance with guidelines 
for Good Manufacturing Practice (Swissmedic no. 
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510793; Wyss Zurich, Zurich, Switzerland) was 
performed as described previously.16,18,21 Briefly, 
dermis and epidermis were separated enzymati-
cally (Fig. 2, above, left), followed by fibroblast and 
keratinocyte isolation and expansion (Fig. 2, sec-
ond row, left, and second row, right).22,23 Keratinocytes 
were cultured in serum-free media (CELLnTEC 
Advanced Cell Systems AG, Bern, Switzerland), 
and fibroblasts were cultured in Dulbecco’s 
Modified Eagle Medium (Sigma-Aldrich, Buchs, 
Switzerland) containing 10% fetal bovine serum 
(Life Technologies, Zug, Switzerland). For graft 
production, fibroblasts were incorporated into 
an acid-soluble bovine collagen type I hydro-
gel (Symatese, Chaponost, France) as described 
previously.18,21,24 After plastic compression of the 
hydrogel and cultivation for 5 to 6 days, keratino-
cytes were seeded at a density of approximately 
0.15 × 106/cm2 onto the surface of the graft.18,22–24 
After additional cultivation,18,22,23 grafts (Fig. 2, 
above, right) were shipped to the study site in a 
cell culture medium–filled tissue culture flask in a 
temperature-regulated transport box at 35 ± 5°C, 
to be grafted within 24 hours. Graft size was 45 ± 
4 cm2, with a thickness of 1 ± 0.5 mm.
Routine testing for sterility, mycoplasma, and 
endotoxins according to the European Pharma-
copoeia were undertaken throughout the manu-
facturing process. Cell identity and purity were 
confirmed using flow cytometry (Fig. 2, fourth 
row, left, and fourth row, right). Quality control 
tests included size and thickness measurements 
(Fig. 2, above, right), assessment of cell number 
(DNA count), cell viability/distribution (fluores-
cein diacetate staining) (Fig. 2, third row, left, and 
third row, right), and histology (hematoxylin/eosin 
staining) (Fig. 2, below).
Grafting Procedure
Grafting was performed by the principal 
investigator (M.M.) and coordinating investiga-
tor (C.S.) under general anesthesia with sterile 
conditions. In acute cases, contaminated and 
devitalized tissues were débrided (Fig. 3, above, 
left), and wound bed conditioning with tempo-
rary allograft coverage was performed to ensure 
Fig. 1. Inclusion/exclusion criteria and study cohort flow chart. (Left) Inclusion and exclusion criteria. (Right) Study cohort flow 
chart. HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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Fig. 2. (Continued).
Copyright © 2019 American Society of Plastic Surgeons. Unauthorized reproduction of this article is prohibited. 
192
Plastic and Reconstructive Surgery • July 2019
a well-vascularized and sterile recipient site. In 
reconstructive cases, the area of pathology was 
excised, creating either a partial- or a full-thick-
ness defect.
Hemostasis was achieved with bipolar cautery 
and epinephrine-soaked gauzes, and the wound 
bed was sprayed with fibrin sealant (ARTISS; Bax-
ter Healthcare, Deerfield, Ill.). Grafts were cut to 
fit the defect (mean, 41 cm2; range, 32 to 49 cm2), 
secured in place using staples (Fig. 3, above, cen-
ter), and dressed with Mepilex (Mölnlycke Health 
Care, Gothenberg, Sweden) and an overlying 
occlusive dressing or a negative-pressure device 
(KCI Vacuum Assisted Closure; Kinetic Concepts, 
Inc., San Antonio, Texas). Remaining defects 
were grafted in accordance with the current stan-
dard of care.
The first dressing change was carried out 
between postoperative days 9 and 11. Thereafter, 
in uncomplicated cases, patients were discharged 
with outpatient follow-up and photographic docu-
mentation at 2, 3, and 4 weeks; 2 and 3 months; 1 
year; and then annually for 5 years thereafter.
Outcome Measures
The primary outcome was “safety” (local infec-
tion and graft take/epithelialization), and the sec-
ondary outcome was “adverse events.” Percentage 
graft take, assessed at the time of the first dressing 
change, and percentage epithelialization, assessed 
at 3 weeks, were determined as follows: standard-
ized photographic documentation, delineation of 
epithelialized and nonepithelialized areas on the 
Fig. 2. (Continued). Bioengineering process of the autologous, 
dermo-epidermal skin substitute. (Above, left) Split-thickness 
skin biopsy specimen (macroscopic view). (Above, right) The 7 
× 7-cm bioengineered skin before grafting, grown in a specially 
designed culture flask. (Second row, left) Phase-contrast micro-
graph of dermal fibroblasts expanded on cell culture plastic. 
(Second row, right) Fluorescein diacetate staining of living der-
mal fibroblasts in the hydrogel. (Third row, left) Fluorescence-
activated cell sorting analysis performed on human dermal 
fibroblasts stained by the fibroblast-specific antibody to CD90 
(red, unstained control; green, isotype control; yellow, CD90-
specific antibody). FITC, fluorescein isothiocyanate. (Third row, 
right) Phase-contrast micrograph of human epidermal kerati-
nocytes expanded on cell culture plastic. (Fourth row, left) Flu-
orescein diacetate staining of a confluent monolayer of living 
keratinocytes on the upper surface of the hydrogel. (Fourth row, 
right) Fluorescence-activated cell sorting analysis performed on 
human epidermal keratinocytes stained by the specific keratin 
markers K5/K8 (red, unstained control; green, isotype control; 
yellow, K5/K8-specific antibody). (Below) Hematoxylin and eosin 
staining of a section of the bioengineered skin, before grafting. 
Arrowheads indicate fibroblasts in the dermal compartment. 
Arrows indicate keratinocyte layers on top of the bioengineered 
skin. Please note the presence of the faint stratum corneum.
Fig. 3. Clinical course of the burn patient. (Above, left) Patient 3 intraoperatively after wound bed preparation. (Above, center) 
After application of the bioengineered skin. (Above, right) Postoperative appearance at day 8. (Below, left) After 3 weeks. (Below, 
center) After 3 months. Please note the grafted bioengineered skin (black arrow) in comparison to the gold standard, meshed split-
thickness skin graft (open arrow), and unaffected, healthy skin (white arrow). (Below, right) After 2 years. The transplanted skin graft 
is almost indistinguishable from healthy skin and is larger when compared to below, center, white arrow.
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photographs by an experienced observer (M.M. 
or C.S.), and percentage calculation using com-
puterized planimetry as proposed by Bloemen et 
al.25 and Boyce et al.26
Scar quality was assessed with the Patient and 
Observer Scar Assessment Scale at 1 year postop-
eratively and annually thereafter (for 5 years). 
Briefly, the Patient and Observer Scar Assess-
ment Scale is a validated scar assessment tool that 
consists of a patient scale and an observer scale, 
whereby scar characteristics are rated from 1 to 10 
(where 1 = normal skin and 10 = worst imaginable 
scar or sensation), and the total scores for each 
scale are calculated.27
All adverse events were handled according to 
the Good Clinical Practice guidelines from the 
International Conference on Harmonisation and 
the Swiss Federal Council’s Regulation on Clinical 
Trials with Medicinal Products. Histologic analyses 
of grafted areas were carried out with an optional 
biopsy at 3 months postoperatively.
Histology
Punch biopsy specimens (3-mm diameter) 
were processed for histology and immunofluo-
rescence as described previously.24 Antibodies 
included anti-human K1 (Novus Biologicals, Lit-
tleton, Colo.), anti-human Lam332 (Santa Cruz, 
Nunningen, Switzerland), anti-human Tropo-
elastin (Elastin Products Co., Owensville, Mo.), 
anti-human CD31 (Dako, Switzerland), and anti-
human Keratin19 (Dako, Switzerland).
RESULTS
Patient Demographics
Between July of 2014 and March of 2016, six 
male and four female patients, aged 8 to 18 years, 
underwent grafting (Table 1). There was one 
patient with acute burns, whereas nine patients 
underwent reconstructive surgery, primarily for 
burn scars (n = 7), at a mean of 9 ± 4 years (range, 7 
to 14 years) after injury. The mean follow-up dura-
tion was 15 ± 7 months (range, 2 to 25 months).
Manufacturing
Cell isolation and expansion from split-thick-
ness skin biopsy specimens (Fig. 2) was successful 
in all 10 biopsy specimens. Grafts were produced 
in a mean ± SD of 32 ± 4 days (range, 26 to 38 
days). All 10 grafts fulfilled the in-process controls 
and release criteria. Grafts maintained their size 
and allowed handling with forceps (Fig. 2).
Pretransplant Histology
Before transplantation, grafts showed an even 
distribution of viable fibroblasts in the dermal 
compartment (Fig. 2, third row, left) and a conflu-
ent layer of viable keratinocytes on the surface 
(Fig. 2, third row, right). Hematoxylin and eosin 
staining confirmed the presence of cells in the 
dermal and epidermal compartments (Fig. 2, 
below).
Outcomes
Main results are shown in Table 1. Briefly, 
mean graft take at days 9 through 11 was 67 ± 32 
percent (range, 0 to 100 percent; median, 65 per-
cent). Patient 9 manipulated the dressing postop-
eratively and suffered total graft loss. Subanalysis 
excluding this patient yielded a mean take of 74 
± 23 percent (range, 50 to 100 percent; median, 
75 percent). Mean epithelialization at day 21 was 
63.5 ± 35 percent (range, 0 to 98 percent; median, 
78 percent). When excluding the noncompliant 
patient, mean epithelialization at day 21 was 70.6 
± 30.6 percent (range, 5 to 98 percent; median, 
80 percent). There were no cases of infection. 
Donor-site healing was uneventful in all cases.
Regarding adverse events, there were four 
cases of hematoma, three of which healed spon-
taneously (patients 1, 4, and 7), whereas one 
required repeated split-thickness skin grafting 
(patient 10). The patient with total graft loss also 
underwent regrafting with split-thickness skin 
graft.
Figure 3 illustrates the clinical course of the 
acute burn patient. After wound bed preparation 
(Fig. 3, above, left), the cultured graft was trans-
planted next to meshed split-thickness skin graft 
and unwounded skin (left arm) Fig. 3, above, cen-
ter). At 8 and 21 days after transplantation, the 
take was 100 percent (Fig. 3, above, right and Fig. 
3, below, left). After 3 months, the bioengineered 
skin (Fig. 3, below, center, black arrow) was smoother 
and more pliable than the neighboring meshed 
split-thickness skin graft (Fig. 3, below, center, open 
arrow) and, except for the redness, was very simi-
lar to the adjacent normal skin (Fig. 3, below, cen-
ter, white arrow). After 2 years, the cultured skin 
(Fig. 3, below, right) was almost indistinguishable 
from normal skin (Fig. 3, below, center, white arrow) 
and had notably grown compared with the size 
at 3 months (Fig. 3, below, center). Patient and 
Observer Scar Assessment Scale scores 1 year post-
operatively for the first eight patients and 2 years 
postoperatively for the first three patients were 










































































































1 15 Male Burn scar* 13.70 Left arm 42 PT tangential 
 excision of scar; 
dermal overgraft-
ing with BESS
50 76 No Hematoma No 25.17
2 17 Female Burn scar* 8.27 Left thigh 45 PT tangential 
 excision of scar; 
dermal overgraft-
ing with BESS
100 86 No  No 23.07





excision of surface 
granulation tissue, 
BESS application
100 90 No  No 25.37
4 18 Male Giant CMN NA Left back 36 FT intralesional 
 excision of nevus; 
BESS application
55 50 No Hematoma No 12.47
5 14 Female Burn scar 6.84 Left chest 49 PT tangential 
 excision of scar; 
dermal overgraft-
ing with BESS
100 98 No  No 11.37




NA Left chest 44 FT scar excision, 
release of tethered 
left breast; BESS 
application
50 100 No  No 13.27
7 11 Male Burn scar 11.27 Left  
forearm
42 PT tangential 
 excision of scar; 
dermal overgraft-
ing with BESS
50 50 No Hematoma No 12.53





 excision of scar; 
dermal overgraft-
ing with BESS
90 80 No  No 12.87
9 11 Male Burn scar 9.80 Left chest Approximately 
32
PT tangential 
 excision of scar; 
dermal overgraft-
ing with BESS






10 11 Male Burn scar* 10.43 Left chest 39 PT tangential 
 excision of 
scar; dermal 
 overgrafting with 
BESS; VAC  
application





CMN, congenital melanocytic nevus; FT, full-thickness; PT, partial-thickness; POD, postoperative day; BESS, bioengineered skin substitute; STSG, split-thickness skin graft.
*Widely meshed pattern.
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Histology
Three months postoperatively, there was a mul-
tilayered, well-stratified epidermis and a dermal 
compartment comparable to native skin (Fig. 4, 
above, left, and above, center). Immunofluorescence 
staining for the basement membrane component 
Laminin332 revealed the deposition of a continu-
ous basement membrane (Fig. 4, above, right). 
Keratin 1 expression was found in all suprabasal 
layers of the epidermis (Fig. 4, above, right). In the 
epidermis, a subpopulation of basal cells were ker-
atin 19–positive (Fig. 4, below, left). Blood vessels 
were found throughout the dermis and in close 
proximity to the dermal-epidermal junction, as 
visualized by staining for CD31 (Fig. 4, below, cen-
ter). Tropoelastin could be detected throughout 
the dermis up to the dermoepidermal junction 
(Fig. 4, below, right).
DISCUSSION
This is a first-in-human clinical trial to evalu-
ate whether a bioengineered, hydrogel-based, 
autologous dermo-epidermal skin substitute can 
be safely used for permanent coverage of skin 
defects in children and adolescents. Favorably, in 
the present setting of nine reconstructive (elec-
tive) cases and one acute burn case, there were no 
safety-related issues recorded. Of note, because 
patient safety was the primary outcome, we delib-
erately chose to treat easily accessible areas, to 
avoid location-associated problems (e.g., neck, 
axilla, thigh). In addition, in the global picture, 
grafting of this novel study product yielded prom-
ising functional and aesthetic long-term outcomes 
(Fig. 3), with nearly normal skin architecture his-
tologically (Fig. 4).
This clinical trial focused exclusively on chil-
dren and adolescents, acknowledging that they 
demonstrate quite high rates of burn injuries and 
other conditions associated with extensive skin 
loss. In addition, children are more susceptible to 
hypertrophic scarring,3 and they are facing dev-
astating consequences of growth in the presence 
of unyielding scars. Theoretically, they could ben-
efit immensely—and notably, more than adults—
from a skin graft that heals with only mild scarring 
and that grows proportionally with the patient.
From a small (4-cm2) skin biopsy specimen, a 
protocol-specified 49-cm2 piece of skin was gen-
erated in approximately 1 month. Of note, this 
manufacturing process would also allow a 70-fold 
expansion (i.e., production of 280 cm2) within the 
same production time, thereby offering a poten-
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with massive burns). This production time, even 
though seemingly long, is similar to the 4 to 5 
weeks required for the skin analogue developed 
by Boyce et al.12 and significantly faster than the 8 
weeks needed for the skin analogue produced by 
Auger et al.13 Nevertheless, it is our explicit goal to 
reduce production time so that more acute cases 
become eligible for this innovative approach.
The preoperative graft histology reveals a one- 
to three-layer epidermis, associated with a col-
lagen- and fibroblast-rich dermis (Fig. 2, below). 
This translates clinically to grafts that are pliable 
and robust enough to be handled surgically. Fur-
thermore, in accordance with our preclinical stud-
ies,15 grafts become readily vascularized (Fig. 4, 
below, center). Postoperatively, grafts have matured 
quickly and without scar hypertrophy (Fig. 3). 
Long-term follow-up demonstrates remarkable 
stability of the grafted skin, with no findings of 
blistering or wound breakdown. This may be 
attributed to an evolving (i.e., possibly not yet 
complete and fully mature) but already function-
ally competent dermoepidermal junction (Fig. 4, 
above, right)8 and a population of self-renewing 
cells in both dermis and epidermis.21
The skin quality of grafted areas compares 
favorably with conventional split-thickness skin 
grafting, as demonstrated visually (Fig. 3) and sup-
ported by Patient and Observer Scar Assessment 
Scale scores 1 year postoperatively (Table 2). The 
parameters relevant for hypertrophic scarring 
(i.e., pliability, thickness, and relief) in the present 
study were scored better than in a large study of 
474 burn patients (284 children) 1 year after split-
thickness skin graft transplantation.28 Importantly, 
subanalysis comparing Patient and Observer Scar 
Assessment Scale scores between adult and pediat-
ric patients did not reveal significant differences.28 
Reassuringly, Patient and Observer Scar Assess-
ment Scale scores for pain (mean, 1.75; SD, 1.49) 
and itching (mean, 1.50; SD, 1.41) were also lower 
than in the quoted study.28 Not astonishingly, the 
least favorable Patient and Observer Scar Assess-
ment Scale scores were seen for the patient param-
eter “skin color.” The reason is hypopigmentation 
that unequivocally occurs because of the paucity 
Fig. 4. Analyses of punch biopsy specimens reveal functional skin, 3 months after grafting. (Above, left) Hematoxylin and eosin 
staining of a 3-mm punch biopsy specimen of the grafted bioengineered skin. Note the functional dermis and the stratified epi-
dermis covered by a stratum corneum. (Above, center) Magnification of the inset (gray frame) in above, left. (Above, right) Staining 
of the continuous basement membrane by an antibody to laminin-332 (red line). A K1 antibody (green) stains suprabasal keratino-
cyte layers, whereas the basal layer is K1-negative. Nuclei stained by Hoechst dye. (Below, left) As expected, and described by us 
previously, K19 expression is restricted to the basal layer. (Below, center) A well-organized dermal capillary plexus is detected by 
an antibody to human-specific CD31 (red). (Below, right) Tropoelastin (green) is reexpressed in the dermis, 3 months after grafting. 
Nuclei are stained by Hoechst dye.
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of melanocytes whenever cultured skin is applied 
clinically.12,16
Our cultured skin analogue contains the 
fundamental elements of skin, a nearly natural 
epidermis and dermis, and a dermo-epidermal 
junction that, from a clinical perspective, appears 
functionally competent. However, like the very few 
comparable versions of bioengineered and clini-
cally applied dermo-epidermal skin analogues, it 
also lacks crucial components, including melano-
cytes, skin appendages, and a neurovascular sup-
ply. We carried out preclinical studies to create a 
more complete skin substitute and demonstrated 
the feasibility of producing and transplanting pig-
mented16 and prevascularized17 skin grafts. Corre-
spondingly, first-in-human studies are planned.
In the current study, the mean graft take rate 
appears somewhat lower than rates typically seen 
with conventional split-thickness skin grafts.12 The 
instances where incomplete take and graft loss 
were higher than expected were mainly attribut-
able to the presence of hematomas,29 rather than 
intrinsic graft problems. Clearly, these hema-
toma complications were also the key factors for 
the relatively low epithelialization rates seen at 
21 days. We encountered this vexing and rather 
unexpected problem despite choosing flat and 
relatively immobile areas for grafting; ensuring 
meticulous hemostasis; and applying fibrin glue, 
the best possible graft fixation, and optimal dress-
ings. We hypothesize that hematoma formation 
results from less efficient clotting cascade trig-
gers in the bioengineered skin compared with 
split-thickness skin graft. Patient medications and 
laboratory coagulation parameters were formally 
reviewed with a hematologist, but no differences 
between the groups (with or without hematomas) 
were observed. Graft take rates were, however, 
similar to rates seen in clinical studies of Boyce et 
al.,26 and also comparable to rates seen when der-
mal regeneration matrices were applied to burn 
wounds, together with an overlying thin split-
thickness skin graft.30 Along the usual learning 
curve that characterizes these types of innovative 
approaches, refinements will be made to both tech-
nique and perioperative management to improve 
take rates in our follow-up studies. Currently, 
three international phase II trials (NCT03394612, 
NCT03229564, and NCT03227146) are ongoing 
to evaluate the study product in a randomized 
intrapatient controlled setting.
The main limitation of this study lies in the 
ethical and regulatory requirements for a first-
in-human phase I study. The outcome variables 
were given and limited. With safety as the primary 
outcome, the formal inclusion of a control was not 
feasible. However, our currently running phase II 
clinical trials are designed as intrapatient random-
ized controlled studies (see above).
Based on the same ethical considerations for 
a phase I study, the number of patients was small 
and the area allowed to graft was formally limited 
to 49 cm2. Phase II trials will have to show what 
occurs when significantly larger areas are grafted 
with the study product.
Furthermore, nine of the 10 patients treated 
were elective cases, whereas only one was a burn 
patient. Even though this burn patient demon-
strated a most favorable course and final outcome, 
the efficacy of the cultured graft for the treatment 
of acute burns must be demonstrated in a larger 
number of acute patients.
Lastly, this phase I clinical trial is only a prelimi-
nary, initial analysis of a few fundamental points—in 
this case, primarily safety and adverse events. The 
present study design does not allow production of 
much more evidence than proof of principle: clini-
cal application of the study product is feasible and 
safe. All other intriguing issues such as details of clin-
ical efficacy (in particular, large-scale transplantation 
and application in demanding areas), comparison 
with other methods, range of indications, potential 
improvements, cost-effectiveness, and more, must 
be and will be addressed in subsequent trials.
CONCLUSIONS
This phase I clinical trial demonstrates that 
a laboratory-engineered, autologous, hydrogel-
based, dermo-epidermal skin substitute can be 
used safely to permanently cover skin defects in 
children and adolescents. There is preliminary evi-
dence that the study product may compare favor-
ably with split-thickness skin grafting in terms of 
both functional and aesthetic long-term results. 
Moreover, this study paved the way for phase II 
clinical trials. Finally, the promising results of the 
present study highlight the potential of this novel 
bioengineered skin substitute to become both a 
life-saving therapy for massive skin defects and a 
viable new approach to treat myriads of patients 
of all ages requiring surgical coverage of a broad 
range of skin defects.
Ernst Reichmann, Ph.D. 
Tissue Biology Research Unit 
Department of Surgery
University Children’s Hospital Zurich
August Forel Strasse 7
8008 Zurich, Switzerland
ernst.reichmann@kispi.uzh.ch
Copyright © 2019 American Society of Plastic Surgeons. Unauthorized reproduction of this article is prohibited. 
198
Plastic and Reconstructive Surgery • July 2019
ACKNOWLEDGMENTS
This project has received funding from the European 
Union’s Seventh Framework Program for research, tech-
nological development, and demonstration under grant 
agreement no. 279024 (FP7/2011–2016 EuroSkin-
Graft), the People Program MultiTERM (FP7-PEOPLE-
2008-ITN) under grant agreement no. 238551, iTERM 
(FP7-PEOPLE-2013-ITN) under grant agreement no. 
607868, and by the Clinical Research Priority Programs 
of the University of Zurich, Switzerland (project Clinical 
Research Priority Programs Skin Grafts for Zurich). The 
authors are particularly grateful to the Fondation Gay-
doul and the sponsors of Dona Tissue (Thérèse Meier 
and Robert Zingg) for their generous financial support 
and interest in their work. Special thanks go to Sarah 
Meyer and Silvia Stüdeli for tremendous support and for 
being a vital part of the manufacturing team, to Julia 
Elrod for relentless constructive activities during the 
final phase of manuscript preparation, and to Gabriela 
Acklin for outstanding photographic work.
REFERENCES
 1. Medina A, Riegel T, Nystad D, Tredget EE. Modified Meek 
micrografting technique for wound coverage in extensive 
burn injuries. J Burn Care Res. 2016;37:305–313.
 2. Mcheik JN, Barrault C, Levard G, Morel F, Bernard FX, 
Lecron JC. Epidermal healing in burns: Autologous kerati-
nocyte transplantation as a standard procedure. Update and 
perspective. Plast Reconstr Surg Glob Open 2014;2:e218.
 3. Berchialla P, Gangemi EN, Foltran F, et al. Predicting sever-
ity of pathological scarring due to burn injuries: A clinical 
decision making tool using Bayesian networks. Int Wound J. 
2014;11:246–252.
 4. Rowan MP, Cancio LC, Elster EA, et al. Burn wound healing and 
treatment: Review and advancements. Crit Care 2015;19:243.
 5. Gallico GG III, O’Connor NE, Compton CC, Kehinde O, 
Green H. Permanent coverage of large burn wounds with 
autologous cultured human epithelium. N Engl J Med. 
1984;311:448–451.
 6. O’Connor NE, Mulliken JB, Banks-Schlegel S, Kehinde O, 
Green H. Grafting of burns with cultured epithelium prepared 
from autologous epidermal cells. Lancet 1981;317:75–78. 
 7. Meuli M, Raghunath M. Burns (part 2): Tops and flops using 
cultured epithelial autografts in children. Pediatr Surg Int. 
1997;12:471–477.
 8. Raghunath M, Meuli M. Cultured epithelial autografts: 
Diving from surgery into matrix biology. Pediatr Surg Int. 
1997;12:478–483.
 9. Gobet R, Raghunath M, Altermatt S, et al. Efficacy of cul-
tured epithelial autografts in pediatric burns and reconstruc-
tive surgery. Surgery 1997;121:654–661.
 10. Chua AW, Khoo YC, Tan BK, Tan KC, Foo CL, Chong SJ. 
Skin tissue engineering advances in severe burns: Review 
and therapeutic applications. Burns Trauma 2016;4:3.
 11. Hansbrough JF, Boyce ST, Cooper ML, Foreman TJ. Burn 
wound closure with cultured autologous keratinocytes and 
fibroblasts attached to a collagen-glycosaminoglycan sub-
strate. JAMA 1989;262:2125–2130.
 12. Boyce ST, Simpson PS, Rieman MT, et al. Randomized, 
paired-site comparison of autologous engineered skin 
substitutes and split-thickness skin graft for closure of exten-
sive, full-thickness burns. J Burn Care Res. 2017;38:61–70.
 13. Auger FA, López Valle CA, Guignard R, et al. Skin equivalent 
produced with human collagen. In Vitro Cell Dev Biol Anim. 
1995;31:432–439.
 14. Boa O, Cloutier CB, Genest H, et al. Prospective study on 
the treatment of lower-extremity chronic venous and mixed 
ulcers using tissue-engineered skin substitute made by the self-
assembly approach. Adv Skin Wound Care 2013;26:400–409.
 15. Schiestl C, Biedermann T, Braziulis E, et al. Skingineering 
II: Transplantation of large-scale laboratory-grown skin ana-
logues in a new pig model. Pediatr Surg Int. 2011;27:249–254.
 16. Böttcher-Haberzeth S, Klar AS, Biedermann T, et al. 
“Trooping the color”: Restoring the original donor skin 
color by addition of melanocytes to bioengineered skin ana-
logs. Pediatr Surg Int. 2013;29:239–247.
 17. Marino D, Luginbühl J, Scola S, Meuli M, Reichmann E. 
Bioengineering dermo-epidermal skin grafts with blood and 
lymphatic capillaries. Sci Transl Med. 2014;6:221ra14.
 18. Braziulis E, Diezi M, Biedermann T, et al. Modified plastic 
compression of collagen hydrogels provides an ideal matrix 
for clinically applicable skin substitutes. Tissue Eng Part C 
Methods 2012;18:464–474.
 19. Braziulis E, Biedermann T, Hartmann-Fritsch F, et al. 
Skingineering I: Engineering porcine dermo-epidermal skin 
analogues for autologous transplantation in a large animal 
model. Pediatr Surg Int. 2011;27:241–247.
 20. Garg RK, Rennert RC, Duscher D, et al. Capillary force seed-
ing of hydrogels for adipose-derived stem cell delivery in 
wounds. Stem Cells Transl Med. 2014;3:1079–1089.
 21. Pontiggia L, Biedermann T, Meuli M, et al. Markers to evalu-
ate the quality and self-renewing potential of engineered 
human skin substitutes in vitro and after transplantation. J 
Invest Dermatol. 2009;129:480–490.
 22. Oostendorp C, Uijtdewilligen PJ, Versteeg EM, et al. 
Visualisation of newly synthesised collagen in vitro and in 
vivo. Sci Rep. 2016;6:18780.
 23. Oostendorp C, Meyer S, Sobrio M, et al. Evaluation of cul-
tured human dermal- and dermo-epidermal substitutes 
focusing on extracellular matrix components: Comparison 
of protein and RNA analysis. Burns 2017;43:520–530.
 24. Hüging M, Biedermann T, Sobrio M, et al. The effect of wound 
dressings on a bio-engineered human dermo-epidermal skin 
substitute in a rat model. J Burn Care Res. 2017;38:354–364.
 25. Bloemen MCT, Van Zuijlen PPM, Middelkoop E. Reliability 
of subjective wound assessment. Burns 2011;37:566–571. 
 26. Boyce ST, Goretsky MJ, Greenhalgh DG, Kagan RJ, Rieman 
MT, Warden GD. Comparative assessment of cultured skin 
substitutes and native skin autograft for treatment of full-
thickness burns. Ann Surg. 1995;222:743–752.
 27. Draaijers LJ, Tempelman FR, Botman YA, et al. The patient 
and observer scar assessment scale: A reliable and feasible 
tool for scar evaluation. Plast Reconstr Surg. 2004;113:1960–
1965; discussion 1966–1967.
 28. van der Wal MB, Vloemans JF, Tuinebreijer WE, et al. 
Outcome after burns: An observational study on burn scar 
maturation and predictors for severe scarring. Wound Repair 
Regen. 2012;20:676–687.
 29. Han HH, Jun D, Moon SH, Kang IS, Kim MC. Fixation of 
split-thickness skin graft using fast-clotting fibrin glue con-
taining undiluted high-concentration thrombin or sutures: 
A comparison study. Springerplus 2016;5:1902.
 30. van Zuijlen PP, van Trier AJ, Vloemans JF, Groenevelt F, Kreis 
RW, Middelkoop E. Graft survival and effectiveness of dermal 
substitution in burns and reconstructive surgery in a one-
stage grafting model. Plast Reconstr Surg. 2000;106:615–623.
